Congenital Myasthenic Syndromes (CMS) are a group of rare genetic disorders that affect the neuromuscular junction, leading to muscle weakness and fatigue. These syndromes are caused by mutations ...

Introduction: This case describes successful response to efgartigimod in the treatment of myasthenic crisis secondary to paraneoplastic disease, and in the perioperative setting. Methods: An elderly ...

Learn more about whether Catalyst Pharmaceuticals, Inc. or Ionis Pharmaceuticals, Inc. is a better investment based on AAII's ...

Baird initiated coverage on Catalyst Pharmaceutical Partners (NASDAQ:CPRX) with an Outperform rating and set a price target ...

Baird analyst Joel Beatty last night initiated coverage of Catalyst Pharmaceuticals (CPRX) with an Outperform rating and $28 price target ...

DAVENPORT & Co LLC reduced its position in shares of argenx SE (NASDAQ:ARGX – Free Report) by 5.1% during the fourth quarter, ...

Fintel reports that on February 4, 2025, Baird initiated coverage of Catalyst Pharmaceuticals (NasdaqCM:CPRX) with a ...

For this study, outcomes were compared between 2 groups of patients with myasthenia gravis: those who developed exacerbations ...

South San Francisco, CA, January 30, 2025 – The California Institute for Regenerative Medicine (CIRM), one of the world’s largest institutions dedicated to regenerative medicine, has awarded nearly ...

The healthcare industry is set for growth due to advancements in targeted treatments and personalized care and the rapid ...

The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors ...